Accurately Detects Orf1ab, N and E Genes with High Throughput
QuantiVirus™ SARS-CoV-2 Test Kit
FDA EUA Approved I CE/IVD Marked I Mexico COFEPRIS Approved
India ICRM Approved I Columbia INVIMA APPROVED
Accurately Detects Orf1ab, N and E Genes with High Throughput
QuantiVirus™ SARS-CoV-2 Test
FDA EUA Approved I CE/IVD Marked I Mexico COFEPRIS Approved
India ICRM Approved I Columbia INVIMA APPROVED
DiaCarta is a leading translational genomics and personalized diagnostics company based in Richmond, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.
HPV mRNA Screening
NGS Targeted Sequencing
CLIA Lab Service
ULTRA-SENSITIVE
XNA Technology
XNA,
ULTRA-SENSITIVE
SuperBDNA™ Technology
SuperbDNA™ technology uses branched DNA to qualitatively or quantitatively measure the presence of target DNA or RNA. Unlike PCR or RT-PCR, SuperbDNA™ technology does not amplify the DNA or RNA in the samples, rather amplifies the signals for detection. Because the amplified signal is proportional to the levels of the target (DNA or RNA) in the samples, the latter is easy to be quantified with a standard curve. SuperbDNA™ technology has been used in FDA-approved clinical applications, including prognosis and monitoring of patients with viral diseases.
FDA Report: DiaCarta COVID-19 Tests Rank Top 3 Among FDA SARS-CoV-2 Reference Panel Tests
According to the recent FDA SARS-CoV-2 Reference Panel Comparative Data released on September 15, among all the FDA EUA tests with returned results, DiaCarta’s QuantiVirusTM SARS-CoV-2 Test and QuantiVirus™ SARS-CoV-2 Multiplex Test both rank within the top 3 for product sensitivity.
KRAS Codon 12 Mutations and Detection
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
HPV-driven Cancers and Somatic Mutations in These Cancers
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Need Help?
